vs
梯瓦制药（TEVA）与西部数据（WDC）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是西部数据的1.6倍（$4.7B vs $3.0B），西部数据净利率更高（61.1% vs 10.2%，领先50.8%），西部数据同比增速更快（31.5% vs 11.4%），过去两年梯瓦制药的营收复合增速更高（11.1% vs -6.6%）
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
西部数据（简称WD）是总部位于美国加利福尼亚州圣何塞的知名数据存储企业，成立于1970年，是全球最大的硬盘驱动器（HDD）制造商之一，产品覆盖消费级、企业级等多元存储场景，为全球客户提供高性能、高可靠性的存储解决方案。
TEVA vs WDC — 直观对比
营收规模更大
TEVA
是对方的1.6倍
$3.0B
营收增速更快
WDC
高出20.1%
11.4%
净利率更高
WDC
高出50.8%
10.2%
两年增速更快
TEVA
近两年复合增速
-6.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $4.7B | $3.0B |
| 净利润 | $481.0M | $1.8B |
| 毛利率 | 56.4% | 45.7% |
| 营业利润率 | 6.4% | 30.1% |
| 净利率 | 10.2% | 61.1% |
| 营收同比 | 11.4% | 31.5% |
| 净利润同比 | 321.7% | 254.2% |
| 每股收益（稀释后） | $0.42 | $4.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TEVAWDC
| Q1 26 | — | $3.0B | ||
| Q4 25 | $4.7B | $2.8B | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.2B | $-1.2B | ||
| Q1 25 | $3.9B | $2.3B | ||
| Q4 24 | $4.2B | $4.3B | ||
| Q3 24 | $4.3B | $4.1B | ||
| Q2 24 | $4.2B | $3.8B |
净利润TEVAWDC
| Q1 26 | — | $1.8B | ||
| Q4 25 | $481.0M | $1.2B | ||
| Q3 25 | $433.0M | — | ||
| Q2 25 | $282.0M | $282.0M | ||
| Q1 25 | $214.0M | $520.0M | ||
| Q4 24 | $-217.0M | $594.0M | ||
| Q3 24 | $-437.0M | $493.0M | ||
| Q2 24 | $-846.0M | $39.0M |
毛利率TEVAWDC
| Q1 26 | — | 45.7% | ||
| Q4 25 | 56.4% | 43.5% | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 50.3% | — | ||
| Q1 25 | 48.2% | 39.8% | ||
| Q4 24 | 50.2% | 35.4% | ||
| Q3 24 | 49.6% | 37.9% | ||
| Q2 24 | 48.6% | 35.9% |
营业利润率TEVAWDC
| Q1 26 | — | 30.1% | ||
| Q4 25 | 6.4% | 28.1% | ||
| Q3 25 | 19.7% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 13.3% | 33.1% | ||
| Q4 24 | -0.7% | 19.9% | ||
| Q3 24 | -1.2% | 18.1% | ||
| Q2 24 | -0.1% | 5.7% |
净利率TEVAWDC
| Q1 26 | — | 61.1% | ||
| Q4 25 | 10.2% | 41.9% | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 6.8% | -24.4% | ||
| Q1 25 | 5.5% | 22.7% | ||
| Q4 24 | -5.1% | 13.9% | ||
| Q3 24 | -10.1% | 12.0% | ||
| Q2 24 | -20.3% | 1.0% |
每股收益（稀释后）TEVAWDC
| Q1 26 | — | $4.73 | ||
| Q4 25 | $0.42 | $3.07 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.24 | $0.72 | ||
| Q1 25 | $0.18 | $1.42 | ||
| Q4 24 | $-0.19 | $1.63 | ||
| Q3 24 | $-0.39 | $1.35 | ||
| Q2 24 | $-0.75 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.6B | $2.0B |
| 总债务越低越好 | — | $4.7B |
| 股东权益账面价值 | $7.9B | $7.1B |
| 总资产 | $40.7B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资TEVAWDC
| Q1 26 | — | $2.0B | ||
| Q4 25 | $3.6B | $2.0B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $2.1B | ||
| Q1 25 | $1.7B | $3.5B | ||
| Q4 24 | $3.3B | $2.3B | ||
| Q3 24 | $3.3B | $1.7B | ||
| Q2 24 | $2.3B | $1.9B |
总债务TEVAWDC
| Q1 26 | — | $4.7B | ||
| Q4 25 | — | $4.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $7.3B | ||
| Q4 24 | — | $7.4B | ||
| Q3 24 | — | $7.4B | ||
| Q2 24 | — | $7.4B |
股东权益TEVAWDC
| Q1 26 | — | $7.1B | ||
| Q4 25 | $7.9B | $5.9B | ||
| Q3 25 | $7.3B | — | ||
| Q2 25 | $6.8B | $5.3B | ||
| Q1 25 | $6.3B | $5.2B | ||
| Q4 24 | $5.4B | $12.1B | ||
| Q3 24 | $6.1B | $11.6B | ||
| Q2 24 | $6.4B | $10.8B |
总资产TEVAWDC
| Q1 26 | — | $15.6B | ||
| Q4 25 | $40.7B | $14.4B | ||
| Q3 25 | $39.9B | — | ||
| Q2 25 | $40.1B | $14.0B | ||
| Q1 25 | $38.4B | $16.4B | ||
| Q4 24 | $39.3B | $25.5B | ||
| Q3 24 | $41.8B | $24.8B | ||
| Q2 24 | $41.3B | $24.2B |
负债/权益比TEVAWDC
| Q1 26 | — | 0.65× | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.89× | ||
| Q1 25 | — | 1.42× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | — |
| 自由现金流经营现金流 - 资本支出 | $1.0B | — |
| 自由现金流率自由现金流/营收 | 21.6% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 2.41× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | — |
8季度趋势，按日历期对齐
经营现金流TEVAWDC
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $672.0M | ||
| Q3 25 | $369.0M | — | ||
| Q2 25 | $227.0M | $746.0M | ||
| Q1 25 | $-105.0M | $508.0M | ||
| Q4 24 | $575.0M | $403.0M | ||
| Q3 24 | $693.0M | $34.0M | ||
| Q2 24 | $103.0M | $366.0M |
自由现金流TEVAWDC
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $599.0M | ||
| Q3 25 | $233.0M | — | ||
| Q2 25 | $131.0M | $675.0M | ||
| Q1 25 | $-232.0M | $379.0M | ||
| Q4 24 | $446.0M | $287.0M | ||
| Q3 24 | $545.0M | $-62.0M | ||
| Q2 24 | $6.0M | $250.0M |
自由现金流率TEVAWDC
| Q1 26 | — | — | ||
| Q4 25 | 21.6% | 21.3% | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 3.1% | -58.5% | ||
| Q1 25 | -6.0% | 16.5% | ||
| Q4 24 | 10.5% | 6.7% | ||
| Q3 24 | 12.6% | -1.5% | ||
| Q2 24 | 0.1% | 6.6% |
资本支出强度TEVAWDC
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 2.6% | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 2.3% | -6.2% | ||
| Q1 25 | 3.3% | 5.6% | ||
| Q4 24 | 3.1% | 2.7% | ||
| Q3 24 | 3.4% | 2.3% | ||
| Q2 24 | 2.3% | 3.1% |
现金转化率TEVAWDC
| Q1 26 | — | — | ||
| Q4 25 | 2.41× | 0.57× | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | 0.80× | 2.65× | ||
| Q1 25 | -0.49× | 0.98× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 9.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
WDC
| Cloud | $2.7B | 89% |
| Client Devices | $176.0M | 6% |
| Consumer | $168.0M | 6% |
